< Back to previous page
Patent
Biomarkers for diabetes therapy
The invention relates to an in-vitro method for identifying a diabetic patient as responder or non-responder to a treatment of Proinsulin, Interleukin 10 and anti-CD3, based on the expression level of at least 1 microRNA, selected from the group consisting of miR-365, miR-34a, miR-193b and miR-125a, in a sample from the diabetic patient prior to said treatment.
Patent Publication Number: EP3775282
Year filing: 2021
Year approval: 2022
Year publication: 2021
Status: Requested
URI: link to Espacenet
Technology domains: Biotechnology
Validated for IOF-key: Yes
Attributed to: Associatie KULeuven